Abiraterone Acetate + ADT Improves Survival in mCSPC Regardless of Visceral Disease Status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study
Eur. J. Cancer 2021 Dec 22;162(xx)56-64, G Baciarello, M Özgüroğlu, S Mundle, G Leitz, U Richarz, P Hu, S Feyerabend, N Matsubara, KN Chi, K FizaziFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.